Register for an account

X

Enter your name and email address below.

Your email address is used to log in and will not be shared or sold. Read our privacy policy.

X

Website access code

Enter your access code into the form field below.

If you are a Zinio, Nook, Kindle, Apple, or Google Play subscriber, you can enter your website access code to gain subscriber access. Your website access code is located in the upper right corner of the Table of Contents page of your digital edition.

Health

Beating B-Cells for MS

Medication targets cells that fuel brain inflammation.

DSC-E0218_18.jpg
Ocrelizumab is the first FDA-approved treatment for primary-progressive MS. | Genentech

Newsletter

Sign up for our email newsletter for the latest science news

More than 400,000 Americans are afflicted with multiple sclerosis, an autoimmune disease that disrupts the brain’s neural signals to the body. In March, the Food and Drug Administration approved the drug ocrelizumab to treat not only the milder form of MS, but also the primary-progressive form, for which there was no treatment until now.

In both types of MS, immune system cells attack and strip away myelin, the fatty protective sheathing that insulates nerve cells. This interferes with nerve signals, causing muscle weakness, lack of coordination, blurry vision, bowel and bladder problems and foggy thinking.

The new-to-market drug takes a novel approach. Whereas traditional MS medications target the immune system’s T-cells, ocrelizumab focuses on destroying the system’s B-cells, which fuel the brain inflammation that causes the disease to worsen.

During clinical trials, MRI scans showed that ocrelizumab reduces new brain inflammation in the milder relapse-remitting form, and slows deterioration in the progressive and most aggressive form. Along the way, the experiments have resulted in important information on how MS attacks the body, says Stephen Hauser, a neurologist at the University of California, San Francisco, whose lab spent decades determining the critical role B-cells play in the disease.

    2 Free Articles Left

    Want it all? Get unlimited access when you subscribe.

    Subscribe

    Already a subscriber? Register or Log In

    Want unlimited access?

    Subscribe today and save 70%

    Subscribe

    Already a subscriber? Register or Log In